KPTI
Karyopharm·NASDAQ
--
--(--)
--
--(--)
5.29 / 10
Netural
Analyst consensus is overwhelmingly bullish (100% Buy) with a historical 100% win rate, and fund-flow metrics show a positive trend (7.8/10). Despite some medium and large flow challenges, the net inflow of capital and strong institutional conviction suggest that smart money remains engaged, potentially providing support for a rebound.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-05
InstitutionCantor Fitzgerald
Times predicted1
Historical Win Rate100.0%
Is money flowing into or out of KPTI?
- KPTI holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.29/10 (Netural).
